VERAXA Biotech (NASDAQ: VRXA) provided a corporate and pipeline update on July 6, 2026, highlighting progress during the first half of the year, including continued advancement of its proprietary BiTAC(R) platform and growing interest from potential pharmaceutical partners. The company's pipeline now includes four BiTAC-based T-cell engager programs targeting solid tumors, two bispecific antibody-drug conjugate (ADC) programs, and two non-BiTAC assets available for partnering.
VERAXA plans to prioritize investment in its BiTAC portfolio while seeking to monetize selected non-BiTAC programs to help finance future development. The goal is to advance lead BiTAC-TCE candidate VXA-102 to IND/CTA readiness by early 2028. This strategic focus underscores the company's commitment to its next-generation cancer therapies.
Company executives cited strong industry interest in T-cell engager and ADC technologies, noting that recent partnering discussions at the BIO International Convention and other scientific meetings reinforced confidence in the company's differentiated BiTAC platform and its potential to secure strategic collaborations. VERAXA continues to refine both its pipeline and partnering strategy as it advances its next generation of cancer therapies.
For more details, the full press release is available at https://ibn.fm/xTF5q. The latest news and updates relating to VRXA are available in the company's newsroom at https://ibn.fm/VRXA.
VERAXA Biotech AG is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. Powered by transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research.
BiTAC(R) is a registered trademark of VERAXA Biotech GmbH. Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties that may cause actual results to differ materially. These forward-looking statements are subject to risks set forth in the company's filings with the SEC. Undue reliance should not be placed on forward-looking statements, and the company undertakes no duty to update this information unless required by law.
